Dark

DRMA
Dermata Therapeutics, Inc. Common Stock
stock NASDAQ

At Close

Dec 16, 2025 3:59:30 PM EST

2.32USD-6.452%(-0.16)57,688

2.23Bid 2.26Ask 0.03Spread

Pre-market

Dec 16, 2025 9:08:30 AM EST

2.45USD-1.210%(-0.03)500

After-hours

Dec 15, 2025 4:07:30 PM EST

2.48USD-0.800%(-0.02)0

OverviewHistoricalExchangesShortsNews

Nov 19, 2021

08:33AM EST Dermata Highlights Presentation Of Results From DMT410 Phase 1b Proof Of Concept Study For Aesthetic Skin Conditions At The American Society For Dermatologic Surgery 2021 Annual Meeting Benzinga

08:20AM EST The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial Benzinga

Nov 17, 2021

08:06AM EST Dermata Therapeutics Reports First Patient Enrolled In Its Phase 2 Trial Of DMT310 For Treatment Of Moderate-To-Severe Rosacea Benzinga

Nov 15, 2021

04:25PM EST Dermata Therapeutics Q3 EPS $(0.86) Benzinga

10:37AM EST The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More Benzinga

Nov 4, 2021

09:53AM EDT Dermata Therapeutics Shares Quiet Following Earlier Post On National Institutes Of Health's ClinicalTrials.gov For Co.'s 'DMT310-005 Topical in the Treatment of Acne Rosacea,' Shows 'Not Yet Recruiting' Benzinga

Nov 3, 2021

11:21AM EDT Dermata Therapeutics, Inc. (DRMA) shares are trading more than 12 percent higher on Wednesday morning, continuing a bullish trend after the company reported positive data for mild to moderate Psoriasis candidates in the Phase 1b trial. There were no corporate announcements on the day to impact the stock alert. RTTNews

Oct 19, 2021

09:22AM EDT Shares of California-based Dermata Therapeutics, Inc. (DRMA), are up more than 5 percent in pre-market after it announced positive topline results from phase 1b clinical trial of DMT310, its lead product candidate for the treatment of mild-to-moderate Psoriasis. RTTNews

06:03AM EDT The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 05.50 A.M. EDT). RTTNews

Oct 18, 2021

04:03PM EDT Dermata Announces Results From Phase 1b Clinical Trial Of DMT310 For The Treatment Of Mild-to-Moderate Psoriasis Benzinga

Sep 30, 2021

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

Sep 27, 2021

04:09PM EDT Dermata Therapeutics 8-K Shows Q2 Results: ~$427K In Cash, EPS $(0.70) vs $(0.43) In Same Qtr. Last Year Benzinga

Sep 21, 2021

10:39AM EDT Brookline Capital Initiates Coverage On Dermata Therapeutics with Buy Rating, Announces Price Target of $14 Benzinga

08:20AM EDT The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data Benzinga

08:10AM EDT Dermata To Present Results From DMT410 Phase 1b Proof Of Concept Aesthetic Study At The American Society For Dermatologic Surgery 2021 Annual Meeting Nov. 19-21 Benzinga

Sep 16, 2021

07:48AM EDT The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study Benzinga

Sep 14, 2021

10:02AM EDT Maxim Group Initiates Coverage On Dermata Therapeutics with Buy Rating, Announces Price Target of $9 Benzinga

07:50AM EDT The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout Benzinga

Sep 5, 2021

01:14PM EDT The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week Benzinga

Sep 1, 2021

07:39AM EDT Dermata Therapeutics, Inc. (DRMA) on Wednesday announced the appointment of Kyri Van Hoose as Senior Vice President and Chief Financial Officer. RTTNews

07:32AM EDT The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering Benzinga

06:56AM EDT Dermata Therapeutics Names Kyri Van Hoose As SVP, CFO RTTNews

06:04AM EDT Dermata Therapeutics, Inc. Announces Appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer Benzinga

Aug 31, 2021

08:15AM EDT The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 15, 2021

12:16PM EDT The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow Benzinga

11:06AM EDT The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow Benzinga

Aug 13, 2021

10:50AM EDT Dermata Therapeutics Shares Open For Trade At $5.80; IPO Priced At $7/Share Benzinga

09:27AM EDT Dermata Therapeutics Shares Will Open For Quote At 10:35 a.m. EDT, Expected To Open For Trade After 10:45 a.m. EDT; IPO Priced At $7/Share Benzinga

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

.dark-mode .Y6qGKS{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .Y6qGKS{ color: #333333; background-color: white; border: 2px solid #333333; }DRMADermata Therapeutics, Inc. Common Stockstock NASDAQ

DRMA
Dermata Therapeutics, Inc. Common Stock
stock NASDAQ